Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology

References

• Goldberg LH, Mamelak AJ. Review ofactinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol. 2010;9:1125–32.
   PubMed Web of Science ®Google Scholar
• Fenske NA, Spencer J, Adam F. Actinic keratoses: past, present and future. J Drugs Dermatol. 2010;9:S45–9.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Fleischer AB. Jr,. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201–7.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ortonne JP, Alomar A. Actinic keratosis and field cancerisation. Eur J Dermatol. 2011;21(Suppl 1):3–12.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Krueger-Corcoran D, Roewert-Huber J, et al. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology. 2010;220:15–24.
   PubMed Web of Science ®Google Scholar
• Fernandez-Figueras MT, Carrato C, Saenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991–7.
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23–4.
   PubMed Web of Science ®Google Scholar
• Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer. 1990;46:356–61.
   PubMed Web of Science ®Google Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – short version. J Eur Acad Dermatol Venereol. 2015;29:2069–79.
   PubMed Web of Science ®Google Scholar
• Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5:19–35.
   PubMed Web of Science ®Google Scholar
• Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol 2013;68(1 Suppl 1):S2–9.
   PubMed Web of Science ®Google Scholar
• Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–9.
   PubMed Web of Science ®Google Scholar
• Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol. 2000;115:273–7.
   PubMed Web of Science ®Google Scholar
• Schwartz RA, Bridges TM, Butani AK, Ehrlich A. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol 2008;22:606–15.
   PubMed Web of Science ®Google Scholar
• Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol 2013;133:1971–8.
   PubMed Web of Science ®Google Scholar
• Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167(Suppl 2):36–42.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251–8.
   PubMedGoogle Scholar
• Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29–35.
   PubMed Web of Science ®Google Scholar
• MacKie RM. Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe. J Eur Acad Dermatol Venereol. 2004;18:552–5.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5 Pt 1):738–43.
   Web of Science ®Google Scholar
• Schmitz L, Kahl P, Majores M, et al. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30:1303–7.
   PubMed Web of Science ®Google Scholar
• Röwert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8–12.
   PubMed Web of Science ®Google Scholar
• Huerta-Brogeras M, Olmos O, Borbujo J, et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol. 2012;148:1159–64.
   PubMedGoogle Scholar
• Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges. 2007;5:970–6.
   PubMedGoogle Scholar
• Zalaudek I, Giacomel J, Schmid K, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol. 2012;66:589–97.
   PubMed Web of Science ®Google Scholar
• Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol. 2015;29(Suppl 1):3–8.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Themstrup L, de Carvalho N, et al. Dynamic optical coherence tomography in dermatology. Dermatology. 2016;232:298–311.
   PubMed Web of Science ®Google Scholar
• Pellacani G, Neri L, Longo C. Comment to: ‘Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis’. J Eur Acad Dermatol Venereol. 2016;30:e114.
   PubMed Web of Science ®Google Scholar
• Rowe DE, Carroll RJ, Day CL. Jr., Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–90.
   PubMed Web of Science ®Google Scholar
• Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.
   PubMed Web of Science ®Google Scholar
• Perez-Reyes N, Farhi DC. Squamous cell carcinoma of head and neck in patients with well-differentiated lymphocytic lymphoma. Cancer. 1987;59:540–4.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat. 2007;18:53–8.
   PubMed Web of Science ®Google Scholar
• Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol. 2013;168:277–83.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Patients' perceptions of topical treatments of actinic keratosis. J Dermatolog Treat. 2014;25:375–9.
   PubMed Web of Science ®Google Scholar
• Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adher. 2013;8:35–41.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Peris K, Guillen C, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol. 2015;54:509–15.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Peris K, Guillen C, et al. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29:298–306.
   PubMed Web of Science ®Google Scholar
• Peris K, Neri L, Fargnoli MC, Pellacani G. Physicians' concerns towards prescription adherence and treatment effectiveness in the clinical management of actinic keratosis. G Ital Dermatol Venereol. 2014;149:193–8.
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34–40.
   PubMed Web of Science ®Google Scholar
• Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687–92.
   PubMed Web of Science ®Google Scholar
• Simon JC, Dominicus R, Karl L, et al. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29:881–9.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18:651–9.
   PubMed Web of Science ®Google Scholar
• Actikerall. Summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/24614. 2014. Accessed July 2016.
   Google Scholar
• Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101–8.
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Dirschka T, Prechtl A, Melzer A. Efficacy of low-dose 5-fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration. J Dtsch Dermatol Ges. 2015;13:430–8.
   PubMed Web of Science ®Google Scholar
• Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007;79(4 Suppl):36–45.
   Web of Science ®Google Scholar
• Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6–S11.
   Web of Science ®Google Scholar
• Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138–49.
   PubMed Web of Science ®Google Scholar
• Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–41.
   PubMed Web of Science ®Google Scholar
• Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265–8.
   PubMed Web of Science ®Google Scholar
• Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg. 2005;31:659–64.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol. 2004;140:1542
   PubMed Web of Science ®Google Scholar
• Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55:324–7.
   PubMed Web of Science ®Google Scholar
• Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677–82.
   PubMed Web of Science ®Google Scholar
• Quirk C, Gebauer K, De'Ambrosis B, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85:318–24.
   PubMed Web of Science ®Google Scholar
• Lacarrubba F, Potenza MC, Gurgone S, Micali G. Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review. J Dermatolog Treat. 2011;22:353–8.
   PubMed Web of Science ®Google Scholar
• Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin Exp Dermatol. 2003;28(Suppl 1):19–23.
   PubMed Web of Science ®Google Scholar
• Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part II. Clinical applications. J Am Acad Dermatol. 2014;70:979–12.
   PubMed Web of Science ®Google Scholar
• Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70:965–12.
   PubMed Web of Science ®Google Scholar
• Alchin DR. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol Ther (Heidelb). 2014;4:157–64.
   PubMedGoogle Scholar
• Zarchi K, Jemec GB. Ingenol mebutate: from common weed to cancer cure. Curr Probl Dermatol. 2015;46:136–42.
   PubMedGoogle Scholar
• Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–9.
   PubMed Web of Science ®Google Scholar
• Ricci F, Tambone S, Neri L, et al. Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: a single arm retrospective study. J Dermatolog Treat. 2016. [Epub ahead of print]. doi: 10.3109/09546634.2016.1161162.
   PubMed Web of Science ®Google Scholar
• Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–90.
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Gupta G, Peris K, et al. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 2014;24:23–7.
   PubMed Web of Science ®Google Scholar
• Kopera D, Kerl H. Visualization and treatment of subclinical actinic keratoses with topical imiquimod 5% cream: an observational study. Biomed Res Int. 2014;2014:135916
   PubMed Web of Science ®Google Scholar
• Hanke CW, Swanson N, Bruce S, et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol. 2011;10:165–70.
   PubMed Web of Science ®Google Scholar
• Gupta G, Stockfleth E, Peris K, et al. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29:1840–2.
   PubMed Web of Science ®Google Scholar
• Tambone S, Fargnoli MC, Capizzi R, Peris K. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series. G Ital Dermatol Venereol. 2015; [Epub ahead of print].
   PubMedGoogle Scholar
• Dirschka T, Peris K, Gupta G, et al. Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment. J Eur Acad Dermatol Venereol. 2016;30:1416–7.
   PubMed Web of Science ®Google Scholar
• Quist SR, Gollnick HP. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Expert Opin Pharmacother. 2011;12:451–61.
   PubMed Web of Science ®Google Scholar
• Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176–81.
   PubMed Web of Science ®Google Scholar
• Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70:30–6.
   PubMed Web of Science ®Google Scholar
• Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151:952–60.
   PubMed Web of Science ®Google Scholar
• Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990–1000.
   PubMed Web of Science ®Google Scholar
• Segatto MM, Dornelles SI, Silveira VB, Frantz GO. Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil. An Bras Dermatol. 2013;88:732–8.
   PubMed Web of Science ®Google Scholar
• Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156–9.
   PubMedGoogle Scholar
• Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6:144–7.
   PubMedGoogle Scholar
• Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629–35.
   PubMedGoogle Scholar
• Epstein E. Does intermittent “pulse” topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol. 1998;38:77–80.
   PubMed Web of Science ®Google Scholar
• Efudix. Summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream. 2014. Accessed July 2016.
   Google Scholar
• Diclofenac sodium 3%. Summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/21229/SPC. 2012. Accessed July 2016.
   Google Scholar
• Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40–3.
   PubMedGoogle Scholar
• Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94–100.
   PubMed Web of Science ®Google Scholar
• Wolf JE, Jr., Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–13.
   PubMed Web of Science ®Google Scholar
• Nelson CG. Diclofenac gel in the treatment of actinic keratoses. Ther Clin Risk Manag. 2011;7:207–11.
   PubMed Web of Science ®Google Scholar
• Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. 2004;30(2 Pt 2):264–71.
   Web of Science ®Google Scholar
• Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29:2342–8.
   PubMed Web of Science ®Google Scholar
• Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171:1164–71.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227–32.
   PubMed Web of Science ®Google Scholar
• Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99–106.
   PubMedGoogle Scholar
• Pariser D, Loss R, Jarratt M, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59:569–76.
   PubMed Web of Science ®Google Scholar
• Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41–6.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160:1066–74.
   PubMed Web of Science ®Google Scholar
• Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013;168:825–36.
   PubMed Web of Science ®Google Scholar
• Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11:1462–7.
   PubMed Web of Science ®Google Scholar
• Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010;9:1101–8.
   PubMed Web of Science ®Google Scholar
• Hoover WD, III, Jorizzo JL, Clark AR, et al. Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis. Cutis. 2014;94:255–9.
   PubMed Web of Science ®Google Scholar
• Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol. 2009;8:35–9.
   PubMed Web of Science ®Google Scholar
• Tavin E, Persky M. Metastatic cutaneous squamous cell carcinoma of the head and neck region. Laryngoscope. 1996;106(2 Pt 1):156–8.
   Web of Science ®Google Scholar